New insider activity at Rocket Pharmaceuticals ( (RCKT) ) has taken place on April 11, 2025.
Kinnari Patel, the President, Head of R&D, and COO of Rocket Pharmaceuticals, has made a significant investment by purchasing 21,099 shares of the company’s stock. This transaction is valued at $99,165, indicating a strong vote of confidence in the company’s future prospects.
Recent Updates on RCKT stock
In the last 24 hours, Rocket Pharmaceuticals has seen varied adjustments in its stock price targets from several financial analysts. BMO Capital initiated coverage with an Outperform rating, highlighting the company’s unique liver-targeted gene therapies, which are expected to offer life-long effects and address diseases with severe unmet needs, such as Danon Disease. Scotiabank slightly raised its price target, reflecting optimism in the company’s advancements. Conversely, Canaccord and Goldman Sachs lowered their targets, possibly due to differing assessments of market conditions or company-specific challenges. Overall, the company’s promising pipeline and financial stability continue to drive positive sentiment despite mixed target adjustments.
Spark’s Take on RCKT Stock
According to Spark, TipRanks’ AI Analyst, RCKT is a Underperform.
Rocket Pharmaceuticals receives a low overall stock score of 26, reflecting significant financial challenges typical for a biotech in the R&D phase, with no revenue and ongoing cash burn. Technical analysis indicates a bearish trend with the stock trading below major moving averages. The negative P/E ratio and lack of dividend yield underscore the speculative nature of the stock, suitable primarily for risk-tolerant investors.
To see Spark’s full report on RCKT stock, click here.
More about Rocket Pharmaceuticals
YTD Price Performance: -57.55%
Average Trading Volume: 2,015,550
Technical Sentiment Signal: Strong Buy
Current Market Cap: $575.8M